Has Uday Bhatt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,002 in general payments to Uday Bhatt, MD across 354 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Uday Bhatt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Uday Bhatt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Uday Bhatt, MD

Interventional Pain Medicine · Hamilton, NJNPI 1033147483

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Nevro Corp. at 42.4% of the total. Reporting peaked in 2021 at $2,935 and has fallen 98.6% since, to $41 in 2024.

$8,002in general payments, 2019–2025

Across 354 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Nevro Corp.$3K
Abbott$1K
Medtronic$686
Boston Scientific$419
Si-bone, Inc.$373
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$307
plus $1K from 20 others

What the payments were for

Food & beverage$8,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Nevro Corp.	139	$3,393
Abbott	91	$1,454
Medtronic	6	$686
Boston Scientific	16	$419
Si-bone, Inc.	8	$373
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	26	$307
Collegium Pharmaceutical, Inc.	21	$304
Stryker	2	$256
Novo Nordisk	1	$120
Amgen	9	$115
Johnson & Johnson	6	$96
Vertos Medical, Inc.	1	$86
Azurity Pharmaceuticals, Inc.	4	$75
AstraZeneca	5	$61
GRT US Holding, Inc.	4	$53
Scilex Pharmaceuticals Inc.	3	$40
Biodelivery Sciences International, Inc.	2	$30
Redhill Biopharma Inc.	2	$29
Stratus Medical, LLC	1	$16
Arbor Pharmaceuticals, Inc.	1	$15
Pfizer	1	$14
Hikma Pharmaceuticals USA	1	$12
Iroko Pharmaceuticals, LLC	1	$12
Pacira Therapeutics, Inc.	1	$12
Fidia Pharma USA Inc.	1	$11
MDD US Operations, LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Omnia$1,018
PROCLAIM$212
CoreValve Evolut$188
PIVOX Oblique Lateral Spinal System$181
Proclaim IPG$131
INTELLIS$131
EVEREST SPINAL SYSTEM$129
TRITANIUM$128
iFuse Implant$123
Ozempic$120
GENERAL PAIN MANAGEMENT$119
COREVALVE EVOLUT R$109
Senza$106
Senza Spinal Cord Stimulation System$106

How this compares

$8,002 in reported general payments places this provider in the 75th percentile of 82 interventional pain medicine providers in New Jersey.

See all interventional pain medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$71,815

Medicare patients

162

Services billed

1,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Diclofenac Sodium	41	$5,229
Lidocaine	29	$2,317
Duloxetine Hcl	41	$554
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	29	$385
Gabapentin	66	$338
Celecoxib	27	$237
Tramadol Hcl	47	$221
Cyclobenzaprine Hcl	28	$165
Meloxicam	22	$45

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Hamilton

Adam SacksteinHamilton$13K
Youssef JosephsonWest Deptford$496K
Ali ValimahomedHolmdel$415K
Saurabh DangEdgewater$157K
Gabriele JasperBrick$114K
Matthew LippChatham$67K
Didier DemesminSomerset$33K
Steve AydinFranklin Lakes$22K
Kieran SlevinHainesport$21K
John CoccaroToms River$17K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →